Edesa Biotech, Inc. (EDSA)

Market Cap	34.72M +138.4%
Revenue (ttm)	n/a
Net Income	-14.10M
EPS	-1.73
Shares Out	13.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,624
Open	2.860
Previous Close	2.700
Day's Range	2.550 - 2.860
52-Week Range	0.720 - 20.320
Beta	1.22
Analysts	Strong Buy
Price Target	16.33 (+535.41%)
Est. Earnings	Dec 11, 2026

About EDSA

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 17
• Stock Exchange: Nasdaq
• Ticker Symbol: EDSA
• Website: https://www.edesabiotech.com

Analyst Summary

According to 2 analysts, the average rating for EDSA stock is "Strong Buy." The 12-month stock price target is $16.33, which is an increase of 535.41% from the latest price.

Price Target

$16.33

(535.41% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 31, 2026

Data Sources Report a data error